Quick Facts: Therapeutic Domain

• Respiratory System Infections: Used for acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, and acute maxillary sinusitis.
• Throat/Sinus Infections: Indicated for pharyngitis and tonsillitis.
• Skin and Tissue: Prescribed for uncomplicated skin and soft tissue infections.
• Gastrointestinal Use: Employed in combination therapy for H. pylori eradication in patients with duodenal ulcer disease.

---

Understanding the Therapeutic Use of Лекоклар

Лекоклар contains the established active substance clarithromycin. It is an anti-infective agent intended to manage a spectrum of bacterial infections susceptible to its action. Its principal role is the treatment of respiratory tract infections, including both upper and lower respiratory conditions. Specifically, it addresses infections in the lungs, such as community-acquired pneumonia, and other conditions like acute bacterial exacerbation of chronic bronchitis and acute maxillary sinusitis.

The medication is also utilized to treat infections of the ear, nose, and throat area, such as tonsillitis and pharyngitis, and is indicated for managing uncomplicated infections that affect the skin and soft tissues. A major use in adults is as part of a multi-drug regimen for the eradication of the bacterium Helicobacter pylori (H. pylori) in individuals with duodenal ulcer disease, which is a key approach to reduce the recurrence of such ulcers. Appropriate use of this and all antibacterial agents is guided by clinical evaluation to ensure treatment targets susceptible organisms, thereby supporting effective patient care and public health safety.

The eligibility for using Лекоклар (Clarithromycin) is strictly defined by regulatory authorities based on age, pre-existing conditions, and physiological status.

Populations for whom use is Contraindicated (Must NOT Use):

• Allergy: Patients with known hypersensitivity to clarithromycin, any macrolide antibiotic, or excipients.
• Cardiac Risk: Individuals with a history of QT prolongation, ventricular arrhythmia (including Torsades de pointes), or uncorrected low potassium or magnesium levels (hypokalaemia/hypomagnesaemia).
• Organ Failure: Patients suffering from severe hepatic failure combined with severe renal impairment.
• History: Those with a history of cholestatic jaundice or liver dysfunction associated with prior clarithromycin use.

Age-Related Eligibility:

• Adults/Adolescents (12+): Film-coated tablets are generally indicated for this age group.
• Children (Under 12): Tablets are not recommended; the oral suspension is the appropriate formulation for children down to six months of age.
• Infants (< 6 months): Safety and efficacy are not established (insufficient data).

Conditional or Restricted Use:

• Renal Impairment: Patients with severe kidney impairment (creatinine clearance < 30 mL/min) must have their dose reduced.
• Pregnancy/Lactation: Use during pregnancy is not recommended unless the benefit clearly outweighs the potential risk. Caution is advised when used by breastfeeding mothers.
• Other Conditions: Caution is advised for patients with impaired hepatic function, Myasthenia Gravis (due to risk of exacerbation), and certain underlying heart conditions (e.g., severe cardiac insufficiency, bradycardia).

Interactions with other medicines and products

Clarithromycin (Лекоклар) is formally documented in regulatory labeling as an inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) transporter. This activity is the basis for most officially documented interactions, which generally lead to increased systemic exposure of co-administered drugs.

Contraindicated Combinations

Certain combinations are strictly prohibited by regulatory authorities due to high risk of serious adverse events. These include Lovastatin and Simvastatin (risk of rhabdomyolysis), Ergotamine and Dihydroergotamine (risk of acute toxicity), and agents like Pimozide and Lurasidone.

Interaction Type	Examples of Affected Co-Drugs
Increased Exposure	Digoxin, Theophylline, Triazolobenzodiazepines, Calcium Channel Blockers
Pharmacodynamic	Oral Hypoglycemics (risk of hypoglycemia)

Specific Restrictions and Requirements

For clarithromycin Extended-Release tablets, administration must be with food to ensure proper systemic absorption, as noted in official prescribing information. Additionally, the co-administration of Colchicine is explicitly contraindicated in patients who have pre-existing renal or hepatic impairment. For the antiviral Zidovudine, administration of clarithromycin tablets requires a minimum 4-hour separation to prevent reduced Zidovudine concentrations.

How Лекоклар Works: Pharmacodynamic Mechanism

Лекоклар (Clarithromycin) acts as a protein synthesis inhibitor by directly targeting the 50S ribosomal subunit within susceptible bacteria. The molecule binds specifically to the 23S ribosomal RNA of this subunit, physically blocking the ribosomal process of translocation, which is essential for adding new amino acids to the peptide chain. This molecular obstruction immediately halts the production of necessary bacterial proteins, resulting in a functional bacteriostatic effect that arrests the organism's ability to grow and replicate.

This core mechanism is supported by the drug’s high concentration within host phagocytes (immune cells), which function as biological carriers to deliver the active compound to deep tissue sites. Furthermore, its active metabolite, 14-(R)-hydroxyclarithromycin, works synergistically with the parent drug, contributing to the total microbial suppression and enabling engagement with host immune processes.

The mechanism is functionally constrained by bacterial resistance, typically through genetic modification of the ribosomal target or expression of bacterial efflux pumps. Separately, Clarithromycin acts as an inhibitor of the human liver enzyme CYP3A4, a host-level mechanism that alters the processing of co-administered medications.

Official Administration Guidelines (Лекоклар - Clarithromycin)

The administration of this medication is strictly defined by regulatory guidelines to ensure appropriate use. The route of administration is oral, with dosing frequency typically set at twice daily (every 12 hours).

Dosing Schedule:

Age Group	Standard Twice-Daily Dose	Severe Infection Dose
Adults & Adolescents (ge 12 years)	250 mg two times per day	500 mg two times per day
Children (6 months to 12 years)	7.5 mg/kg body weight two times per day (using oral suspension)	Dose may be increased up to 500 mg two times per day

Special Conditions and Preparation:

Clarithromycin tablets or oral suspension may be taken with or without food. The oral suspension (granules) must be properly reconstituted with a specific amount of water by a pharmacist or caregiver, and the bottle should always be shaken well before use to ensure accurate dosing. The recommended duration of treatment is generally 6 to 14 days, but the full course prescribed by the physician must be completed to prevent infection recurrence.

For patients with severe renal impairment (creatinine clearance < 30 mL/min), the total daily dosage must be reduced by half (e.g., 250 mg once daily). If a dose is missed, patients should skip the missed dose and continue with the next scheduled dose at the usual time; do not double the dose to compensate. This structured protocol ensures the correct dosage and administration method are maintained throughout the prescribed therapy.

Research Evidence / Overview of Studies for Лекоклар

This overview summarizes the key clinical studies and research patterns associated with Лекоклар (Clarithromycin). The purpose is to describe the scope of the available evidence according to official and scientific sources, without offering any clinical advice or individual predictions. Findings describe group patterns observed under specific research conditions.

---

Evidence Supporting Use in Respiratory Tract Infections

Research has been conducted exploring the use of this medicine in conditions like community-acquired pneumonia, acute exacerbation of chronic bronchitis, and infections of the sinuses and throat. Studies conducted include Randomized Controlled Trials (RCTs) and comparative trials.

Researchers monitored several key outcomes related to how symptoms change over time. These included short-term measurements of investigator assessment of clinical status or resolution of infection and bacteriological response rates. Findings describe patterns observed in studies that evaluated the rate of achieving certain measured clinical and microbiological endpoints. The evidence contributes to the broader landscape by providing insight into short-term changes in both clinical and laboratory markers.

---

Evidence Supporting Use for H. pylori Eradication

Лекоклар was evaluated in a multi-drug regimen (often called triple therapy) for the eradication of the H. pylori bacterium in adults with duodenal ulcer disease. Studies explored this combination therapy primarily through RCTs and systematic reviews.

Reports describe patterns that the measured eradication rates may be declining globally. Research highlights the significance of clarithromycin resistance in H. pylori isolates as a primary factor influencing the measured outcome of the regimen. Therefore, the certainty remains low regarding predicted outcomes in regions where the resistance rate is high.

---

Research Gaps and Uncertainties

One of the most significant research limitation frames is the global increase in macrolide resistance. The utility of the drug in practice appears closely related to local resistance patterns, and the research documentation notes that comparative evidence is limited for many new or region-specific resistant strains.

Furthermore, sample sizes were modest in some specific sub-group analyses, meaning results apply only to the populations studied. Research provides context but not individual predictions for all possible clinical scenarios.

Common questions about Лекоклар (FAQ)

---

Q: What is the main therapeutic purpose of Лекоклар?

A: Official documents state that this medicine is approved to treat a variety of bacterial infections. This includes certain respiratory, skin, and ear infections, as well as specific infections caused by H. pylori (stomach ulcers) and Mycobacterium avium complex (MAC).

Q: Is Лекоклар effective against infections caused by viruses like the common cold or flu?

A: Regulatory documents clarify that antibiotics, including this medication, only work against bacteria. Therefore, it is not effective for treating infections caused by viruses, such as the common cold or flu.

Q: What specific types of bacteria is Лекоклар designed to target?

A: Official information indicates this drug targets specific bacterial isolates that are susceptible to the macrolide class of antibiotics. These include bacteria responsible for certain cases of pneumonia, bronchitis, sinus, throat, and skin infections.

Q: Why is Лекоклар sometimes prescribed as part of a treatment plan for stomach ulcers?

A: The medication is approved for use alongside other medicines to treat ulcers caused by the bacterium H. pylori. The goal is to eliminate this specific bacterium, which is associated with duodenal ulcer disease.

Q: What is the reason for the common side effect of a bitter or metallic taste when taking Лекоклар?

A: Official labeling reports an abnormal taste (dysgeusia) as a frequently observed side effect in clinical studies. While the specific biological reason for this taste is complex, it is a commonly acknowledged event listed in regulatory documentation.

Q: How common are digestive side effects like nausea, vomiting, or diarrhea when using Лекоклар?

A: Official product information indicates that digestive issues like diarrhea, nausea, and abdominal pain are among the most frequently reported adverse events in clinical trials. The majority of these effects are described in studies as being mild and temporary.

Q: Are there any major signs of a serious allergic reaction to Лекоклар that require immediate attention?

A: Regulatory documents describe the potential for severe acute hypersensitivity reactions, which are described in official warnings. Signs may include difficulty breathing, swelling of the face, lips, or throat, and serious skin reactions such as Stevens-Johnson syndrome.

Q: Can Лекоклар cause dizziness or affect a person's ability to drive or operate machinery?

A: Official documents list potential central nervous system (CNS) effects such as dizziness, confusion, and vertigo as infrequent side effects. Official warnings suggest that these effects may impact attention or coordination.

Q: Is it possible for Лекоклар to cause changes in heart rhythm or affect the heart's electrical activity?

A: The medication has been associated with prolongation of the QT interval (a measure of the heart's electrical recovery) and infrequent cases of arrhythmia. Official sources include warnings and precautions regarding its use in patients with pre-existing heart conditions.

Q: Are long-term side effects known after completing a course of Лекоклар?

A: Epidemiological and observational studies have investigated a possible rare, delayed risk of adverse cardiovascular outcomes (cardiovascular mortality). This potential long-term risk has been explored in certain patients who have pre-existing coronary artery disease.

Q: Does Лекоклар interact with or worsen pre-existing anxiety or depression?

A: Official post-marketing surveillance has included reports of psychiatric adverse reactions, such as anxiety, insomnia, and confusion. These reports highlight the possibility of effects on mood and mental state.

Q: Is tooth or tongue discoloration a known side effect of Лекоклар?

A: Official product information sometimes lists tooth discoloration and tongue discoloration as reported side effects. Reports suggest that this discoloration is typically temporary and may resolve after the treatment is finished.

Q: Why do official sources warn about severe diarrhea (C. difficile) with Лекоклар?

A: Regulatory documents warn that, like almost all antibiotics, this drug can alter the normal balance of intestinal flora. This change can potentially lead to an overgrowth of the bacterium C. difficile, which is the cause of severe diarrhea (CDAD).

Q: What are the signs of liver issues that may be linked to taking Лекоклар?

A: Official sources report potential liver dysfunction associated with the drug. Signs mentioned in labeling may include loss of appetite, jaundice (yellowing of the skin or eyes), dark urine, or a tender abdomen.

Q: Can Лекоклар be taken with common over-the-counter pain relievers like ibuprofen or paracetamol?

A: Official drug information addresses the need for individuals to inform their healthcare provider about all substances being taken, including over-the-counter pain relievers. This is because all drugs have the potential to interact.

Q: Does Лекоклар interact with common cholesterol-lowering medicines (statins)?

A: The official prescribing information indicates that co-administration with certain statins (specifically lovastatin and simvastatin) is contraindicated. This is due to a significantly increased risk of muscle toxicity (rhabdomyolysis).

Q: What precautions are necessary if a person has kidney or liver problems before taking Лекоклар?

A: The drug is processed by the liver and kidneys, so caution is advised in patients with impaired hepatic function (liver problems). Official guidelines indicate that severe renal impairment (kidney problems) is a condition that requires adjustment to the standard dosage.

Q: Is it necessary to avoid alcohol completely while using Лекоклар?

A: While regulatory labels may not mandate complete alcohol avoidance, general health information notes that heavy alcohol consumption may potentially affect the body's immune response to the infection.

Q: Can using Лекоклар affect blood sugar levels, especially for people with diabetes?

A: Official documentation reports hypoglycemia (low blood sugar) as a potential adverse effect. This effect is particularly noted when the medication is used alongside certain types of anti-diabetic medications.

Q: What other common prescription drugs have a serious interaction warning with Лекоклар?

A: Regulatory information warns that the drug is strictly contraindicated for use with several other medications. These include certain heart rhythm drugs (like cisapride) and the gout medication colchicine, due to the risk of serious toxicity or life-threatening arrhythmias.

Q: Why is Лекоклар not recommended for people with certain pre-existing heart conditions?

A: The drug is contraindicated in patients with a history of QT prolongation or a type of ventricular arrhythmia. Caution is also advised for those with existing coronary artery disease or severe cardiac insufficiency, due to the risk of cardiac events.

Q: Does Лекоклар interact with herbal supplements or vitamins?

A: Regulatory advice emphasizes caution regarding the use of all substances, including vitamins, minerals, and herbal supplements. These products also have the potential for drug interactions that should be reviewed.

Q: Why are people with Myasthenia Gravis advised to use caution with Лекоклар?

A: Official product information advises that the drug should be used with caution in patients who have Myasthenia Gravis. This is because there are reports that the medication may potentially exacerbate (worsen) the existing condition.

Q: How long after starting Лекоклар should a person expect to feel better?

A: Official medication summaries often state that a person should typically begin to feel better during the first few days of the prescribed treatment course.

Q: How long does Лекоклар stay in the body after the last tablet is taken?

A: The drug's half-life is described in the Pharmacokinetics section of official regulatory documents. This value is used by professionals to estimate the time it takes for half of the drug to be eliminated from the body, which is typically a few hours for the active compound.

Q: How quickly does the bitter taste side effect usually go away after stopping the medicine?

A: Official adverse event summaries generally characterize the common side effects as 'mild and transient'. Reports suggest that most will typically resolve after the course of treatment has been fully completed.

Q: Can Лекоклар be used to prevent infections, or only to treat existing ones?

A: According to official sources, the medication is approved for both the treatment and prophylaxis (prevention) of disseminated Mycobacterium avium complex (MAC) infection in certain patient populations.

Q: How long is the oral suspension form of Лекоклар stable after it has been mixed?

A: Official label instructions specify that the oral suspension, once mixed (reconstituted), should be stored at room temperature (e.g., 15 to 30 C). The product should be used within 14 days of reconstitution to maintain stability.

Q: Is it true that the oral suspension form of Лекоклар contains sugar?

A: The official excipients list for the oral suspension confirms that it contains sucrose (sugar). Because of this, some official labels include specific information or warnings for patients who have diabetes.

Q: Is there a different way the liquid form of Лекоклар works compared to the tablets?

A: Both the tablet and suspension formulations contain the same active ingredient, clarithromycin. Regulatory documents indicate that the fundamental mechanism of action is identical regardless of the physical form of the medicine.

Q: Is Лекоклар usage considered safe during pregnancy or breastfeeding according to official guidelines?

A: Official prescribing documents advise that the medication should be used during pregnancy only after a careful assessment of the potential benefits and risks. Information also indicates that the active compound may pass into breast milk.

Q: Are there any specific research findings about the use of Лекоклар in the elderly population?

A: Regulatory documents address the use of the drug in the elderly population, noting that older adults may be more susceptible to certain side effects. Specific mentions include drug-associated effects on the QT interval (heart rhythm) which are described in official safety sections.

Q: Have long-term studies been conducted on the safety profile of Лекоклар?

A: Epidemiological studies have been conducted to investigate the potential risk of long-term adverse cardiovascular outcomes in patients with pre-existing coronary artery disease. These studies examine the drug's safety profile over an extended period.

Q: Why is there sometimes an option for an extended-release (XL) version of the active ingredient?

A: The extended-release (XL) version is noted in official documents as an approved dosage form. This formulation is designed to release the drug more slowly over time, allowing for a once-daily schedule instead of the standard twice-daily schedule.

The storage and disposal of Лекоклар (Clarithromycin) must conform to specific regulatory requirements to maintain the product's stability and ensure safety.

Storage Conditions

Product Form	Required Conditions	Stability Period
Granules (Unreconstituted)	Store below 25 C.	Until expiration date.
Oral Suspension (Prepared)	Store between 15 C and 30 C (Do not refrigerate).	Use within 14 days of reconstitution.

Handling and Protection

• The suspension must be shaken well before each administration.
• The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Лекоклар by pouring it down a drain or discarding it into household waste. Patients must consult a pharmacist or local waste management authority for the official procedure regarding pharmaceutical waste disposal, which often includes drug take-back programs.